INDIAN PHARMACOPOEIA COMMISSION
Why in News?
- The Indian Pharmacopoeia Commission (IPC) under the Ministry of Health & Family Welfare, Government of India, participated in the 10th Anniversary Meeting of the South-East Asia Regulatory Network (SEARN).
- The meeting was held in Kathmandu, Nepal, on 4–5 August 2026.
- A major milestone was the recognition of IPC as the WHO-SEARN Regional Centre of Excellence in Pharmacovigilance and Technical Centre in Quality.
- The recognition acknowledges India’s contribution towards strengthening medicine safety, pharmaceutical quality standards and regulatory capacity across the WHO South-East Asia Region.
SOUTH EAST ASIA REGULATORY NETWORK
- SEARN is a collaborative platform established by the WHO South-East Asia Regional Office (SEARO).
- It was established in 2016 to strengthen regulatory systems across Member States.
- It promotes:
- Knowledge sharing
- Regulatory convergence
- Capacity building
- Regulatory reliance mechanisms
- Its thematic working groups focus on:
- Quality assurance
- Pharmacovigilance
- Clinical trials oversight
- Regulatory preparedness
- Medical device regulation
MAIN OBJECTIVES
To improve access to safe, effective and quality-assured medical products across the WHO South-East Asia Region.
Indian Pharmacopoeia Commission (IPC)
- IPC is an institution under the Ministry of Health & Family Welfare, Government of India.
- It plays an important role in developing and promoting standards for medicines in India.
- At the SEARN meeting, IPC highlighted India’s efforts to strengthen the country’s drug regulatory system and promote access to quality-assured medicines through internationally harmonised standards.
KEY CONTRIBUTIONS OF IPC
IPC showcased several important initiatives:
1. Indian Pharmacopoeia
- IPC develops and publishes the Indian Pharmacopoeia, which provides standards for the identity, purity and quality of medicines.
2. Reference Standards
IPC has established:
- Indian Pharmacopoeia Reference Substances (IPRS)
- Impurity Reference Standards (IMPRS)
These support quality testing and pharmaceutical quality control.
3. Pharmacovigilance
- IPC supports pharmacovigilance activities through the Pharmacovigilance Programme of India (PvPI).
- Pharmacovigilance involves monitoring and assessing the safety of medicines and identifying adverse effects.
4. Materiovigilance
- IPC also supports the Materiovigilance Programme of India (MvPI).
- It focuses on monitoring the safety of medical devices.
5. Capacity Building
- IPC conducts capacity-building programmes and works with national and international stakeholders to strengthen regulatory expertise.
RECOGNITION BY WHO SEARN
IPC has been recognised as: Regional Centre of Excellence in Pharmacovigilance and Technical Centre in Quality
Significance of the Recognition
The recognition reflects IPC’s contribution towards:
- Strengthening pharmacovigilance systems.
- Improving pharmaceutical quality standards.
- Building regulatory capacity across the region.
- Promoting pharmacopoeial science and standards.
- Supporting knowledge sharing among Member States.
- Encouraging regulatory harmonisation and convergence.
- Strengthening regional cooperation in medicine regulation.
10TH ANNIVERSARY MEETING OF SEARN
The meeting brought together representatives from:
- National Regulatory Authorities (NRAs)
- Pharmacopoeias
- International organisations
- Regulatory institutions from across the WHO South-East Asia Region
KEY ISSUES DISCUSSED
The meeting provided a platform to discuss emerging challenges in pharmaceutical regulation, including:
- Quality assurance
- Medicine safety
- Regulatory reliance
- Digital transformation
- Regional regulatory cooperation
- Strengthening regulatory systems
What is Pharmacovigilance?
- Pharmacovigilance refers to the monitoring, detection, assessment and prevention of adverse effects or other medicine-related problems.
- It is important for ensuring the safety and effective use of medicines after they enter the healthcare system.
What is Materiovigilance?
- Materiovigilance refers to the monitoring and assessment of adverse events and safety issues associated with medical devices.
- In India, these activities are supported through the Materiovigilance Programme of India (MvPI).
IMPORTANCE FOR INDIA
The recognition strengthens India’s position in the regional pharmaceutical regulatory system.
It can help India:
- Share its regulatory expertise with neighbouring countries.
- Strengthen medicine safety monitoring.
- Promote internationally aligned quality standards.
- Build regulatory capacity across the South-East Asia Region.
- Improve cooperation among national regulatory authorities.
- Contribute to the availability of safe, effective and quality-assured medical products.
CONCLUSION
The recognition of the Indian Pharmacopoeia Commission as the WHO-SEARN Regional Centre of Excellence in Pharmacovigilance and Technical Centre in Quality marks an important achievement for India’s pharmaceutical regulatory system. It highlights India’s growing role in pharmacovigilance, medicine quality, regulatory capacity-building and regional cooperation, while supporting the wider goal of ensuring safe, effective and quality-assured medical products across the South-East Asia Region.
Note: Connect with Vajirao & Reddy Institute to keep yourself updated with latest UPSC Current Affairs in English.
Note: We upload Current Affairs Except Sunday.